Kedrion Leads the Charge on Secondary Immunodeficiencies at IPIC 2025

Kedrion Biopharma's Role in Addressing Secondary Immunodeficiencies at IPIC 2025

Kedrion Biopharma, a leading player in the field of biopharmaceuticals, marks its participation in the International Primary Immunodeficiencies Congress (IPIC) 2025 held in Prague from November 5-7, 2025. The company is particularly focused on shedding light on Secondary Immunodeficiencies (SIDs), a topic gaining traction within the immunology community. This year, Kedrion has organized a Satellite Symposium titled "Secondary Immunodeficiencies in Hematologic Malignancies: A Growing Area of Interest," which underscores the significance of addressing these complex medical challenges.

The symposium opened with remarks from Dr. Fabian Peissker of Kedrion's Medical Affairs team, followed by contributions from prominent experts including Prof. Hermann Wolf from Sigmund Freud University, Austria, and Dr. Federica Pulvirenti from Policlinico Umberto I, Italy. They presented insights into the challenges faced in diagnosing and managing SIDs, particularly in patients grappling with B-cell malignancies. Discussions revolved around real-world clinical experiences, providing an interactive platform for Q&A, which was immensely beneficial for clinicians and researchers in attendance.

Understanding Secondary Immunodeficiencies
SIDs pose a significant clinical hurdle, particularly among patients with hematological malignancies where the risk of severe infections is notably elevated. Advances in cancer treatments have led to improved patient survival, yet complications such as hypogammaglobulinemia can detrimentally affect treatment outcomes and the quality of life. The early identification and management of these conditions, including immunoglobulin replacement therapies, are paramount to mitigate risks associated with infection and enhance patient care.

Kedrion Biopharma's involvement at IPIC 2025 reflects its steadfast dedication to advancing education and fostering collaboration in the medical community regarding SIDs. The company sponsored the symposium as part of an overarching strategy to engage more deeply in the evolving field of immunodeficiency management.

The Importance of Collaborative Knowledge
In addition to the satellite symposium, Kedrion maintains a robust presence at the congress through a dedicated booth, three scientific poster sessions, and involvement of international delegates, illustrating their commitment to innovation in immunodeficiency care. The poster sessions are particularly noteworthy as they feature collaborative insights and new research developed jointly with patient advocacy groups, enriching the dialogue surrounding SIDs. Kedrion's booth also includes a Medical Information Corner, providing participants direct access to medical and scientific personnel for in-depth discussions.

Roberto Crea, Kedrion's Therapeutic Area Lead in Immunology, pointed out the need for more research into the complex interactions between Primary and Secondary Immunodeficiencies. He stated, "Research is essential for a better understanding of these interrelated conditions, ultimately leading to enhanced patient support and outcomes. Our goals include raising awareness about the clinical needs these patients face and fostering collaboration across the healthcare system. Only through unified efforts can we truly improve the quality of life for those affected by SIDs."

Martine Pergent, the President of the International Patient Organization for Primary Immunodeficiencies (IPOPI), echoed the sentiment of collaboration in her insights. She explained the necessity of expanding focus from just Primary Immunodeficiencies (PIDs) to include the overlapping complexities of SIDs. Pergent emphasized the value of integrating experiences from managing chronic diseases, as this approach is vital in addressing SIDs effectively.

IPIC serves as a pivotal platform for exchanges involving over 900 participants representing more than 70 countries, promoting multidisciplinary dialogue focused on immunodeficiencies. The Kedrion-sponsored Satellite Symposium is open to all attendees, highlighting the latest scientific developments in SIDs and offering a chance for deeper engagement with industry experts at Kedrion's booth (#17).

For further information and insights, attendees are encouraged to visit Kedrion's official website at www.kedrion.com, where additional resources related to immunodeficiency management can be found.